Analyst notes from Wedbush on losing patience with Elon Musk, Goldman Sachs on downgrading U.S. GDP, and Convera on equities.

In today’s CEO Daily: Diane Brady on Mark Carney—financier, central banker, and Canada’s new prime minister. The big story: ...

Here's the story ... of one of the most iconic families in television history! The Brady Bunch followed the lives of the Brady family as they navigated living in a blended family, and over 50 ...

Wedbush Securities is making a big statement on Tesla (NASDAQ:TSLA), naming it to its Best Ideas List even though the stock has had a rough start to the year. According to analyst Dan Ives, Tesla ...

Wedbush has a “Outperform” rating and a $90.00 price objective on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share.

As previously reported, Wedbush analyst Alicia Reese upgraded Logitech (LOGI) to Outperform from Neutral with a price target of $125, up from $100, after management clarified during the company ...

In a truly unexpected turn of events, Irina Shayk and Tom Brady are seemingly back together! Despite breaking up in early 2024, they’re allegedly back on. “The timing was off before ...

Wedbush Securities is making a big statement on Tesla (NASDAQ:TSLA), naming it to its Best Ideas List even though the stock has had a rough start to the year. According to analyst Dan Ives, Tesla is ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) – Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush analyst D.